Anthropic Just Became a Drug Company (Sort Of)

Claude Science stores the full audit trail for every output: the source code, the software versions, the input data, a plain-language description of methodology, and the complete conversation history that led to the result. If someone wants to rerun a figure six months later with a different axis scale, the system can do that and show its work.

It also includes a built-in fact-checking agent that verifies citations, audits calculations, and flags figures that no longer match their underlying code. For an industry where a single misplaced decimal can delay a drug by years, that's not a nice-to-have; it's table stakes.

And crucially, all of this can run on a company's own infrastructure. Claude Science supports local installation, remote SSH connections to existing high-performance computing clusters, and on-demand GPU pools. Sensitive preclinical data never has to leave your servers. That's a significant advantage over fully cloud-hosted alternatives in an industry obsessed (rightly) with data privacy.

The Speed Claims Are Eye-Popping

Anthropic and its early partners aren't shy about the numbers. One pharma partner reportedly cut clinical study report drafting from 12 weeks to 10 minutes using Claude-based tools. Novo Nordisk is among the companies that have tested earlier versions.

Novartis CEO Vas Narasimhan has suggested that AI could shrink drug approval timelines from roughly 12–14 years by about 2–4 years, and potentially double success rates from around 8% to 16%. Those are bold projections, and they come with caveats. Target validation (picking the right biological mechanism to go after) remains an unsolved problem that no AI has cracked. But trimming years off the computational and documentation-heavy parts of R&D? That's plausible.

At the launch event, Anthropic's healthcare lead Zubair Jandali put it bluntly: Claude can "run the work, not help with it, not accelerate it, even run it."

The Awkward Part: Anthropic Wants to Make Drugs, Too

This is where things get interesting. Anthropic isn't just selling shovels to gold miners. It's also staking its own mining claim.

The company has launched an internal drug discovery program focused on neglected diseases, backed by a grants program offering up to $20,000 in API credits per project for up to 50 research teams. Applications close July 15, with notifications by July 31.

Analysts at Temperature Zero flagged the obvious tension: Anthropic is "creating potential conflicts with its own customer base" by crossing from tool provider into active drug developer. If Bristol Myers Squibb is paying for Claude Science (and BMS has already deployed Claude Enterprise to over 30,000 employees), how does it feel about its AI vendor also hunting for drug assets?

It's the classic platform dilemma. Amazon sells you cloud services and competes with your products. Google runs your ads and builds rival apps. Anthropic wants to power pharma's R&D and discover its own medicines. The neglected-disease focus gives it moral cover for now, but pharma executives will be watching the boundaries closely.

A Crowded Kitchen With a New Chef

Claude Science enters an AI drug discovery market that's already buzzing. Specialized biotechs like Recursion, Insilico Medicine, and Exscientia have pushed AI-designed molecules into mid-stage clinical trials. Google's Isomorphic Labs leverages DeepMind's AlphaFold technology for structure-based discovery. The overall market sits somewhere between $2.5 billion and $5 billion in 2025, depending on who's counting, with double-digit annual growth expected through the 2030s.

But most of those players compete at the model or pipeline level. Anthropic is playing a different game: the workflow layer. It's betting that the company controlling where scientists actually do their work will capture more long-term value than any individual algorithm. It's the difference between building a better oven and owning the entire restaurant.

The early partner list supports that theory. AstraZeneca, Sanofi, Genmab, AbbVie, the Allen Institute, and the Howard Hughes Medical Institute are all working with Anthropic on life sciences applications. Genmab specifically announced a partnership to build Claude-powered agentic AI for R&D and clinical development workflows.

The Risk Nobody Wants to Talk About

There's a deeper concern lurking beneath the excitement, and analysts aren't ignoring it. When an AI generates a hypothesis and checks its own homework, you've got what Temperature Zero calls the "generator-evaluator consistency problem." If the same family of models creates the science and validates it, errors can become systematic and nearly invisible.

Claude Science's multi-agent review system is designed to catch mistakes, but it's still Claude reviewing Claude. For regulatory-grade work where patient safety hangs in the balance, independent human validation isn't optional. Anthropic acknowledges this; their materials emphasize that Claude Science is an augmentation layer, not a replacement for expert judgment.

But as the tools get faster and the productivity gains get more seductive, that line will be tested constantly. The real question isn't whether Claude Science works. It's whether the humans using it will trust but verify, or just trust.

The Bottom Line

Claude Science is the most ambitious play yet by a major AI company to own the biopharma research workflow. It's genuinely impressive in scope: 60+ databases, multi-agent orchestration, full audit trails, and infrastructure flexibility that respects pharma's data paranoia. The early efficiency numbers are staggering.

But Anthropic is also making a bet that's harder to execute than any algorithm: convincing a nearly $1.8 trillion industry to hand over its most sensitive workflows to a company that's simultaneously building its own drug programs and growing revenue at a pace that would make most SaaS companies blush (from $1.4 billion to nearly $4.5 billion in annualized revenue in just four months). That's a lot of plates spinning at once. The pharma world will be watching to see which ones drop.

The Cancer Company That Just Bought a Lung Drug

Zymeworks, an oncology biotech known for its HER2-targeting cancer drugs, just dropped $929 million to buy a COPD lung treatment. The financing structure is clever, the strategic logic is surprisingly sound, and the real test comes in August.